Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis

Published:2019-07-15 Issue:2 Volume:200 Page:168-174
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Dempsey Timothy M.¹^ORCID,Sangaralingham Lindsey R.²³^ORCID,Yao Xiaoxi⁴^ORCID,Sanghavi Darshak³,Shah Nilay D.²⁴^ORCID,Limper Andrew H.¹²

Affiliation:

1. Department of Pulmonary and Critical Care Medicine

2. Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, and

3. OptumLabs, Cambridge, Massachusetts

4. Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota; and

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.201902-0456OC

Reference43 articles.

1. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline

2. Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan

3. A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis

4. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

5. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias;Respiratory Research;2024-07-31

2. Mechanisms of Bleomycin-induced Lung Fibrosis: A Review of Therapeutic Targets and Approaches;Cell Biochemistry and Biophysics;2024-07-02

3. The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry;Respiratory Research;2024-06-21

4. Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis;PLOS ONE;2024-06-13

5. Improving Accessibility to Patients with Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America;International Journal of Environmental Research and Public Health;2024-05-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3